A Clinical Trial of Injectable Testosterone Undecanoate as a Potential Male Contraceptive in Normal Chinese Men1
Gui-yuan Zhang,
Yi-qun Gu,
Xing-hai Wang,
Yu-gui Cui and
William J. Bremner
Department of Endocrinology, National Research Institute for Family
Planning (G.-y.Z), Beijing 100081, China; Population Center for
Research in Reproduction, Department of Medicine, University of
Washington, (Y.-q.G., W.J.B), Seattle, Washington 98195; Jiangsu Family
Planning Research Institute, (X.-h.W.) Jiangsu 210029, China; and the
Department of Endocrinology, Nanjing Medical University (Y.-g.C.),
Jiangsu 210029, China
Address all correspondence and requests for reprints to: William J. Bremner, M.D., Ph.D., Department of Medicine, University of Washington, Box 356420, Seattle, Washington 98195. E-mail:
wbremner{at}u.washington.edu
This is a pilot dose-finding study of spermatogenic suppressionusing
testosterone undecanoate (TU) injections alone in normalChinese men.
Thirty-two healthy men were recruited. Volunteersunderwent
pretreatment evaluation, then a treatment period inwhich group I
(n = 13) received 500 mg TU, group II (n = 12)received 1000
mg TU, and group III (n = 7) received placebo,respectively, at
monthly intervals during the treatment period(or until azoospermia was
achieved). Thereafter, they underwenta recovery period until all
parameters returned to pretreatmentlevels. Eleven of 12 volunteers in
the 500-mg TU group, andall volunteers in the 1000-mg TU group became
azoospermic. Fastersuppression of spermatogenesis was achieved in the
1000-mg TUgroup. Serum testosterone increased significantly in the
higherdose group at weeks 8 and 12, but remained within the normal
range.Mean serum LH and FSH were profoundly suppressed by both doses
toundetectable levels at week 16. TU injections did not causea
significant change in high density lipoprotein cholesterollevels. No
serious side-effects were found. We conclude thatboth dosages of TU
can effectively, safely, and reversibly suppressspermatogenesis in
normal Chinese men.
This article has been cited by other articles:
B. Kornmann, E. Nieschlag, M. Zitzmann, J. Gromoll, M. Simoni, and S. Von Eckardstein Body Fat Content and Testosterone Pharmacokinetics Determine Gonadotropin Suppression After Intramuscular Injections of Testosterone Preparations in Normal Men
J Androl,
September 1, 2009;
30(5):
602 - 613.
[Abstract][Full Text][PDF]
Y. Gu, X. Liang, W. Wu, M. Liu, S. Song, L. Cheng, L. Bo, C. Xiong, X. Wang, X. Liu, et al. Multicenter Contraceptive Efficacy Trial of Injectable Testosterone Undecanoate in Chinese Men
J. Clin. Endocrinol. Metab.,
June 1, 2009;
94(6):
1910 - 1915.
[Abstract][Full Text][PDF]
S. T. Page, J. K. Amory, and W. J. Bremner Advances in Male Contraception
Endocr. Rev.,
June 1, 2008;
29(4):
465 - 493.
[Abstract][Full Text][PDF]
C. Wang, Y.-G. Cui, X.-H. Wang, Y. Jia, A. Sinha Hikim, Y.-H. Lue, J.-S. Tong, L.-X. Qian, J.-H. Sha, Z.-M. Zhou, et al. Transient Scrotal Hyperthermia and Levonorgestrel Enhance Testosterone-Induced Spermatogenesis Suppression in Men through Increased Germ Cell Apoptosis
J. Clin. Endocrinol. Metab.,
August 1, 2007;
92(8):
3292 - 3304.
[Abstract][Full Text][PDF]
A. Qoubaitary, C. Meriggiola, C. M. Ng, L. Lumbreras, S. Cerpolini, G. Pelusi, P. D. Christensen, L. Hull, R. S. Swerdloff, and C. Wang Pharmacokinetics of Testosterone Undecanoate Injected Alone or in Combination With Norethisterone Enanthate in Healthy Men
J Androl,
November 1, 2006;
27(6):
853 - 867.
[Abstract][Full Text][PDF]
K. L. Matthiesson and R. I. McLachlan Male hormonal contraception: concept proven, product in sight?
Hum. Reprod. Update,
July 1, 2006;
12(4):
463 - 482.
[Abstract][Full Text][PDF]
B.M. Brady, J.K. Amory, A. Perheentupa, M. Zitzmann, C.J. Hay, D. Apter, R.A. Anderson, W.J. Bremner, P. Pollanen, E. Nieschlag, et al. A multicentre study investigating subcutaneous etonogestrel implants with injectable testosterone decanoate as a potential long-acting male contraceptive
Hum. Reprod.,
January 1, 2006;
21(1):
285 - 294.
[Abstract][Full Text][PDF]
L. P. Ly, P. Y. Liu, and D. J. Handelsman Rates of suppression and recovery of human sperm output in testosterone-based hormonal contraceptive regimens
Hum. Reprod.,
June 1, 2005;
20(6):
1733 - 1740.
[Abstract][Full Text][PDF]
Y.-L. Gui, C.-H. He, J. K. Amory, W. J. Bremner, E-X. Zheng, J. Yang, P.-J. Yang, and E.-S. Gao Male Hormonal Contraception: Suppression of Spermatogenesis by Injectable Testosterone Undecanoate Alone or With Levonorgestrel Implants in Chinese Men
J Androl,
September 1, 2004;
25(5):
720 - 727.
[Abstract][Full Text][PDF]
D. B. O'Connor, J. Archer, and F. C. W. Wu Effects of Testosterone on Mood, Aggression, and Sexual Behavior in Young Men: A Double-Blind, Placebo-Controlled, Cross-Over Study
J. Clin. Endocrinol. Metab.,
June 1, 2004;
89(6):
2837 - 2845.
[Abstract][Full Text][PDF]
Y.-q. Gu, J.-s. Tong, D.-z. Ma, X.-h. Wang, D. Yuan, W.-h. Tang, and W. J. Bremner Male Hormonal Contraception: Effects of Injections of Testosterone Undecanoate and Depot Medroxyprogesterone Acetate at Eight-Week Intervals in Chinese Men
J. Clin. Endocrinol. Metab.,
May 1, 2004;
89(5):
2254 - 2262.
[Abstract][Full Text][PDF]
S. von Eckardstein, G. Noe, V. Brache, E. Nieschlag, H. Croxatto, F. Alvarez, A. Moo-Young, I. Sivin, N. Kumar, M. Small, et al. A Clinical Trial of 7{alpha}-Methyl-19-Nortestosterone Implants for Possible Use as a Long-Acting Contraceptive for Men
J. Clin. Endocrinol. Metab.,
November 1, 2003;
88(11):
5232 - 5239.
[Abstract][Full Text][PDF]
L. Turner, A. J. Conway, M. Jimenez, P. Y. Liu, E. Forbes, R. I. McLachlan, and D. J. Handelsman Contraceptive Efficacy of a Depot Progestin and Androgen Combination in Men
J. Clin. Endocrinol. Metab.,
October 1, 2003;
88(10):
4659 - 4667.
[Abstract][Full Text][PDF]
M. C. Meriggiola, T. M.M. Farley, and M. T. Mbizvo A Review of Androgen-Progestin Regimens for Male Contraception
J Androl,
July 1, 2003;
24(4):
466 - 483.
[Full Text][PDF]
Y.-Q. Gu, X.-H. Wang, D. Xu, L. Peng, L.-F. Cheng, M.-K. Huang, Z.-J. Huang, and G.-Y. Zhang A Multicenter Contraceptive Efficacy Study of Injectable Testosterone Undecanoate in Healthy Chinese Men
J. Clin. Endocrinol. Metab.,
February 1, 2003;
88(2):
562 - 568.
[Abstract][Full Text][PDF]
R. A. Anderson and D. T. Baird Male Contraception
Endocr. Rev.,
December 1, 2002;
23(6):
735 - 762.
[Abstract][Full Text][PDF]
R. A. Anderson, D. Kinniburgh, and D. T. Baird Suppression of Spermatogenesis by Etonogestrel Implants with Depot Testosterone: Potential for Long-Acting Male Contraception
J. Clin. Endocrinol. Metab.,
August 1, 2002;
87(8):
3640 - 3649.
[Abstract][Full Text][PDF]
D. Kinniburgh, H. Zhu, L. Cheng, A.T. Kicman, D.T. Baird, and R.A. Anderson Oral desogestrel with testosterone pellets induces consistent suppression of spermatogenesis to azoospermia in both Caucasian and Chinese men
Hum. Reprod.,
June 1, 2002;
17(6):
1490 - 1501.
[Abstract][Full Text][PDF]
A. Kamischke, T. Heuermann, K. Kruger, S. von Eckardstein, I. Schellschmidt, A. Rubig, and E. Nieschlag An Effective Hormonal Male Contraceptive Using Testosterone Undecanoate with Oral or Injectable Norethisterone Preparations
J. Clin. Endocrinol. Metab.,
February 1, 2002;
87(2):
530 - 539.
[Abstract][Full Text][PDF]
A. Kamischke, S. Venherm, D. Plöger, S. von Eckardstein, and E. Nieschlag Intramuscular Testosterone Undecanoate and Norethisterone Enanthate in a Clinical Trial for Male Contraception
J. Clin. Endocrinol. Metab.,
January 1, 2000;
86(1):
303 - 309.
[Abstract][Full Text]